Arthritis and rheumatism
-
Arthritis and rheumatism · Feb 2009
Randomized Controlled Trial Comparative StudyEvaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
To determine the efficacy and safety of pamapimod (a selective inhibitor of the alpha-isoform of p38 MAP kinase) as monotherapy in comparison with methotrexate (MTX) treatment in adult patients with active rheumatoid arthritis (RA). ⋯ The present results showed that pamapimod was not as effective as MTX in the treatment of active RA.